Physician profile
Alok Vij
NPI 1851682900
$191,516.88
in general payments reported to CMS, 2019-2025
15 companies · $80K in 2025
The $80K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.68 · 2021: $88.27 · 2022: $388 · 2023: $277 · 2024: $111K · 2025: $80K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $174K · Travel and Lodging: $7,836 · Consulting Fee: $5,951 · Food and Beverage: $3,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $173,942.30 |
| Travel and Lodging | $7,835.59 |
| Consulting Fee | $5,950.50 |
| Food and Beverage | $3,271.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $137,747.64 | 2021-2025 | Libtayo, Dupixent |
| Mimedx Group, INC. | $52,768.52 | 2024-2025 | |
| Surgenex LLC | $248.00 | 2025 | Renograft, Pellograft, Surgraft |
| Vector Surgical, LLC | $150.00 | 2022 | |
| Genentech USA, INC. | $137.66 | 2022 | |
| Abbvie INC. | $87.89 | 2023 | |
| Ucb, INC. | $70.66 | 2022 | |
| Allergan, INC. | $70.04 | 2019-2022 | |
| Kerecis Limited | $58.83 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Organogenesis INC. | $44.22 | 2024-2025 | Affinity |
| Convatec INC. | $41.39 | 2025 | |
| Amgen INC. | $33.64 | 2023 | Otezla |
| Sun Pharmaceutical Industries INC. | $31.07 | 2023 | Ilumya |
| Novartis Pharmaceuticals Corporation | $17.18 | 2021 | |
| Biofrontera INC. | $10.14 | 2024 | Rhodoled Xl, Ameluz, Xepi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alok Vij listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.